Journal
NATURE COMMUNICATIONS
Volume 10, Issue -, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41467-019-11812-7
Keywords
-
Categories
Funding
- La Ligue Contre le Cancer (Programme Cartes d'Identite des Tumeurs(R) (CIT))
- INCa
- Canceropole PACA
- DGOS (labellisation SIRIC)
- INSERM
- National Institutes of Health [R01 CA178627, R01 DK52913]
- Linda T. and John A. Mellowes Endowed Innovation and Discovery Fund
- Theodore W. Batterman Family Foundation, Inc
Ask authors/readers for more resources
Genetic studies have advanced our understanding of pancreatic cancer at a mechanistic and translational level. Genetic concepts and tools are increasingly starting to be applied to clinical practice, in particular for precision medicine efforts. However, epigenomics is rapidly emerging as a promising conceptual and methodological paradigm for advancing the knowledge of this disease. More importantly, recent studies have uncovered potentially actionable pathways, which support the prediction that future trials for pancreatic cancer will involve the vigorous testing of epigenomic therapeutics. Thus, epigenomics promises to generate a significant amount of new knowledge of both biological and medical importance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available